By Chris Wack
Autonomix Medical shares were up 24% to $4.10 after the company said it received a patent from the U.S. Patent and Trademark Office.
The medical device company said the patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers technology including systems, methods and devices for interventionalply treating cancerous tumors and cancer-related pain.
The Woodlands, Texas, company said it is developing its technology to initially focus on pancreatic cancer pain relief.
A previous preclinical study showed the company's nerve ablation technique significantly reduced metastases and tumor mass in mice, highlighting the role of neural pathways in pancreatic cancer.
Autonomix said it is currently conducting a human clinical trial aimed at pain reduction via nerve ablation near the pancreas, with future studies planned to validate these preclinical results in clinical settings.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 30, 2024 13:37 ET (18:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。